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a b s t r a c t
The Epstein-Barr virus (EBV) predominantly establishes a latent infection in B lymphocytes, but a small
percentage of infected cells switch from the latent state to the lytic cycle, leading to potent viral DNA
replication and progeny viruses production. We here focused on a lytic gene BGLF3.5, and ﬁrst
established BGLF3.5 mutants by marker cassette insertion. Unexpectedly, this insertion mutant failed
to produce BGLF4 protein and thus progeny production was severely inhibited. Then we carefully made
two point mutant viruses (stop codon insertion or frame-shift mutation) and found that BGLF3.5 is not
essential for EBV lytic replication processes, such as viral gene expression, DNA replication, or progeny
production in the HEK293 cells although its homolog in murine gammaherpesvirus 68 (MHV-68) was
reported to be essential. In addition, we examined the roles of two short, upstream open reading frames
within the 50UTR of BGLF3.5 gene in translation of BGLF4.
& 2015 Elsevier Inc. All rights reserved.
Introduction
The Epstein-Barr virus (EBV) is a human gamma-herpesvirus that
is present in most of the world's population. Its genome is approxi-
mately 170 kb in length and encodes more than 80 genes, reﬂecting
the large size of this virus and its complicated lifecycle. EBV is
transmitted via saliva, mostly during infancy or childhood, from close
members of the family. Upon infection, it establishes a latent inf-
ection predominantly in B cells and remains in the host for a lifetime.
Primary EBV infection during infancy is generally asymptomatic, but
that during adolescence or adulthood can cause infectious mono-
nucleosis. EBV is also associated with several human malignancies,
including Burkitt lymphoma, Hodgkin lymphoma, nasopharyngeal
carcinoma (NPC), and gastric cancer (Murata et al., 2014; Young and
Rickinson, 2004).
EBV can establish two types of infection in cells: latent and lytic
(Murata et al., 2014; Murata and Tsurumi, 2013b). In the latent state,
EBV genomic DNA exists in the nucleus as an episome, chromatinized
with histones, and expresses only a limited number of latent viral
genes (Lieberman, 2013). During the lytic cycle, all EBV lytic genes are
expressed, potent viral DNA genome replication occurs, and ﬁnally
progeny virus particles are produced (Hammerschmidt and Sugden,
2013; Tsurumi et al., 2005).
The switch from the latent state to the lytic state is called rea-
ctivation. Physiological stimuli that trigger viral reactivation in vivo
are unclear, but in cultured cells, reactivation can be triggered by
chemical and biological agents, including 12-O-tetradecanoylphor-
bol-13-acetate (TPA), histone deacetylase (HDAC) inhibitors, calcium
ionophores, anti-immunoglobulin (anti-Ig), and/or Transforming gro-
wth factor-beta (TGF-beta) (Murata and Tsurumi, 2013a, 2013b).
Otherwise, reactivation can be fully induced by the exogenous
expression of one of the viral immediate-early (IE) genes, BZLF1
(Zta, Z, ZEBRA, or EB1). As a b-Zip transcription factor, BZLF1 can
efﬁciently induce the expression of early (E) genes, such as the DNA
polymerase catalytic subunit (BALF5), DNA polymerase processivity
factor (BMRF1), and single-stranded DNA-binding protein (BALF2).
Using these enzymes and proteins categorized in E class, EBV
potently ampliﬁes its genome in a rolling circle manner. Replication
of the EBV genome occurs at discrete sites in the nucleus, called
replication compartments (Chiu et al., 2013; Daikoku et al., 2005).
Replication is followed by the production of late (L) genes, which
encode viral structural proteins, such as the major capsid protein
(MCP) and glycoproteins (Sugimoto et al., 2013). The assembled
icosahedral capsid structure encases the viral genome DNA, and the
nucleocapsid buds into the nuclear membrane, acquires tegument
proteins, wears envelope with glycoproteins to ﬁnally from a progeny
virus particle (Amon and Farrell, 2005; Tsurumi et al., 2005).
Although EBV genes expressed during latent infection have been
studied extensively, those expressed in the lytic cycle are not well
characterized. Some of the lytic genes have never been described.
One of these genes, BGLF3.5, is located between BGLF3 and BGLF4,
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and it is conserved among alpha/gamma-herpesviruses [UL14 of
herpes simplex virus (HSV), open reading frame (ORF) 35 of Kaposi's
sarcoma-associated herpesvirus (KSHV) and murine gammaherpes-
virus 68 (MHV-68)], but not among beta-herpesviruses (Mills et al.,
2003). HSV UL14 is a tegument protein that regulates nuclear
translocation of the alpha-transinducing factor (VP16) (Ohta et al.,
2011; Yamauchi et al., 2008): it was also reported to have anti-
apoptotic effect (Yamauchi et al., 2003) and heat shock protein-like
functions (Yamauchi et al., 2002). UL14 knockout viruses exhibited
smaller plaque size, and lower or slower progeny production by
approximately one order of magnitude (Yamauchi et al., 2008). As for
gamma-herpesviruses, transposon mutagenesis screening indicated
that ORF35 of MHV-68 is essential for lytic replication (Song et al.,
2005), but no other information is available in the literature to date.
In order to deﬁne the role of the BGLF3.5 gene, we prepared an
EBV BGLF3.5 insertion mutant for comparison with the wild-type
virus. The mutant showed reduced progeny production that was
proved to be due to the loss of BGLF4 expression. The introduction of
nonsense or frameshift mutations in the gene caused no signiﬁcant
reduction in the virus yield, indicating that the BGLF3.5 gene is not
required for lytic replication of EBV, at least in HEK293 cells. In
addition, physiological signiﬁcance of two upstream ORFs (uORFs) in
the 50UTR of BGLF3.5 coding region was analyzed by introducing
point mutations at the initiation codons of the ORFs of EBV.
Results
Construction of BGLF3.5 insertion mutant
To analyze the biological functions of the EBV BGLF3.5 gene, we
ﬁrst constructed BGLF3.5-deﬁcient recombinant virus (dBGLF3.5-Ins)
as shown in Fig. 1A. In the 462-nucleotides (nts) ORF of BGLF3.5, a
marker cassette, containing the neomycin resistance gene and the
streptomycin sensitivity gene (Neo/St), was inserted between nts 60
and 61, in order to disrupt the gene. We inserted the cassette here
because the nts 1–14 of BGLF3.5 ORF overlap with the terminus of
BGLF3 ORF, and nts 341–462 of BGLF3.5 overlap with starting ORF of
BGLF4 (Fig. 1A). The cassette was then replaced with a wild-type
BGLF3.5 sequence to prepare the revertant virus (dBGLF3.5/R).
These recombinant EBV genomes were analyzed by BamHI and
EcoRI digestion, followed by agarose gel electrophoresis (Fig. 1B
and C). The BamHI-G fragment was present in the wild-type and
revertant (dBGLF3.5/R) viruses (Fig. 1B, white arrow), but the
corresponding bands of dBGLF3.5-Ins virus migrated slower in
the gel by about 1.6 kb (Fig. 1B, white arrowhead), which is the size
of the cassette. The EcoRI digestion pattern of the dBGLF3.5-Ins
virus was almost identical to that of the wild-type and revertant
viruses, because the cassette was inserted into the second largest
fragment, and the shift could not be distinguished in the gel.
Recombinant EBV DNAs were introduced into HEK293 cells, and
hygromycin-resistant cell colonies were cloned for further analysis.
Screening was performed using immunoblotting (IB) analysis to dete-
rmine whether lytic infection could be induced by the exogenous
expression of BZLF1.
Viral protein expression, DNA replication, and progeny production by
the BGLF3.5 insertion mutant
In order to characterize the recombinant viruses, the expression of
lytic viral proteins was ﬁrst determined by IB (Fig. 2A). We selected
two typical cell clones of each EBV-BAC (wild-type, dBGLF3.5-Ins, and
dBGLF3.5/R) for the following analyses. Proteins were prepared from
the HEK293 cell clones latently containing the recombinant EBV
genome 0 or 2 days after electroporation with the expression vector
for BZLF1. Although background expression levels (day 0) of some of
the proteins (e.g., BALF2, BMRF1) were not necessarily constant
between the cell clones, the induction levels of BZLF1 (IE), BALF2,
and BMRF1 (E) genes were comparable (Fig. 2A). Production of gB
(L) might be decreased in the dBGLF3.5-Ins mutants, if only slightly
(Fig. 2A). Unexpectedly, however, we found that the induction of
BGLF4, an E class gene encoding EBV PK, which is located just
downstream of BGLF3.5, was severely inhibited in the two knockout
mutant clones, and accordingly, hyper-phosphorylation levels of
BMRF1, a substrate of BGLF4 PK, were reduced (Fig. 2A, dBGLF3.5-Ins).
We then compared the levels of viral DNA synthesis in HEK293
cells with the wild-type and recombinant viruses. qRT-PCR analysis
demonstrated that viral DNA levels of dBGLF3.5-Ins virus were slightly
lower than, but almost comparable to, those of the wild-type and
revertant viruses (Fig. 2B), indicating that BGLF3.5 does not signiﬁ-
cantly affect viral DNA synthesis of the EBV genome, if any.
Fig. 1. Construction of the EBV BGLF3.5 insertion mutant. (A) Schematic depiction
of EBV genome recombination using a selection marker cassette. Tandemly
arranged neomycin-resistance and streptomycin-sensitivity genes were inserted
between nucleotides (nts) 60 and 61 of the BGLF3.5 gene to generate dBGLF3.5-Ins.
The Neo/St cassette was then replaced with a wild-type BGLF3.5 sequence to
construct the revertant virus dBGLF3.5/R. (B,C) Electrophoresis of the recombinant
viruses. EBV BAC DNAs were digested with BamHI (B) or EcoRI (C), and separated in
an agarose gel. The white arrow indicates the BamHI-G fragment of the virus, and
the white arrowhead indicates the size of the BamHI-G fragment plus the marker
cassette.
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To determine the virus yield, HEK293 cells carrying EBV-BAC
clones were transfected with the BZLF1 expression vector to induce
lytic replication. The cells were harvested together with the culture
medium 3 days after transfection, followed by freezing and thawing.
After centrifugation to clear the cell debris, the supernatants were co-
cultured with EBV-negative Akata cells [Akata(-)] and analyzed using
FACS. Since the recombinant EBV expresses GFP protein, Akata(-)
cells infected with the virus become GFP-positive. The fraction of
Akata(-) cells that were GFP-positive reached 2.7% and 3.8% in wild-
type viral clones and 3.9% and 5.9% in revertant viral clones, but only
0.35% and 0.23% in cells with knockout virus. These results suggest
that BGLF3.5 is not essential for viral protein expression (besides
BGLF4 PK), viral DNA replication, or progeny virus production, but
might be involved in efﬁcient progeny maturation.
Trans-complementation with BGLF4 restored infectivity of the
BGLF3.5 insertion mutant
Because progeny yield of the BGLF3.5 insertion mutant were
reduced to 1/5 to 1/10 of the wild-type or revertant virus, we then
tested whether expression of BGLF3.5 in trans could restore the
reduced virus yield. We also tested BGLF4 PK, as the expression of
this gene was severely restricted in the BGLF3.5 knockout mutant
viruses. Without any exogenous supply (Fig. 3A, white bars), the
knockout viruses showed signiﬁcantly lower virus production
(0.20%) than the wild-type (0.80%). Exogenous supply of BGLF3.5
(Fig. 3A, gray bars) to the deletion viral cultures did not increase
the low titer (0.11%). However, a co-transfection of Flag-tagged
BGLF4 PK (Fig. 3A, black bars) resulted in an increase in the viral
titer to the same level as that of the wild-type virus. Exogenous
expression of BGLF4 PK in the wild-type virus did not increase
viral titer, suggesting that the increase in titers observed with
BGLF4 expression in trans was speciﬁc to BGLF3.5 knockout.
Protein expression patterns are shown in Fig. 3B.
We previously reported that BGLF4 PK knockout EBV exhibited
almost no decrease in viral protein expression or lytic viral DNA
replication, but the deletion inhibited the production of infectious
progeny viruses (Murata et al., 2009a). Taken together, these data
indicate that the reduced viral titer in the BGLF3.5 insertionmutant is
most likely due to the loss of BGLF4 PK, but not of BGLF3.5.
Construction of EBV at BGLF3.5 point mutants
We speculated that the insertion of a large cassette sequence
into the BGLF3.5 gene might affect BGLF4 PK expression. To
exclude the possible involvement of BGLF4, we prepared viruses
with point mutations instead of insertion mutation in the BGLF3.5
gene, expecting that such point mutations would disrupt BGLF3.5
but would not affect BGLF4 PK expression (Fig. 4). Thus, two types
of mutations were introduced: insertion of stop codons (dBGLF3.5-
Stop) and a single nucleotide deletion (dBGLF3.5-Frame), which
causes a frameshift within the ORF (Fig. 4A). For stop codon
insertion, G(nt58)AA to TAA and A(nt61)AG to TAG changes were
made to introduce two consecutive stop codons. For frame shift
mutation, A(nt62) was omitted, which causes premature termina-
tion and disruption of the BGLF3.5 protein. After the construction
of recombinant BAC DNAs, the integrity of the viral genomes was
examined by restriction enzyme digestion, followed by agarose gel
electrophoresis (Fig. 4B). DNA sequencing conﬁrmed that the
nucleotide alterations were as intended.
Viral protein expression, DNA replication, and progeny production by
BGLF3.5 point mutant and wild-type viruses were comparable
The levels of viral lytic proteins expressed by HEK293 cell lines
carrying recombinant EBV were examined after BZLF1 transfection
Fig. 2. Viral protein expression (A), DNA synthesis (B), and progeny production
(C) in wild-type, BGLF3.5 insertion mutant, and revertant viruses. (A) HEK293
cells, latently infected with the indicated EBV genomes, were transfected with
the BZLF1 expression vector, and harvested on day 2. IB was carried out using
anti-BZLF1, -BALF2, -BMRF1, -BGLF4, -gB (BALF4, also termed gp110), and
-tubulin antibodies. (B) HEK293 cells with the indicated EBV genomes were
transfected with the BZLF1 expression vector, and harvested on day 2. Levels of
viral DNA were determined by qRT-PCR as described in the Materials and
Methods. Three independent transfections were carried out for measurement
of EBV genome and control DNAs. Statistical analysis was carried out using
Student's t test and * indicates po0.05 whereas # indicates p40.05. (C) HEK293
cells carrying the indicated EBV genomes were transfected with the BZLF1
expression vector, and harvested on day 3. After freezing/thawing, the super-
natants were co-cultured with Akata(-) cells. GFP-positive cells were counted by
FACS. Independent three biological replicates were assayed and Student's t test
was carried out. ** indicates po0.005.
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(Fig. 5A). We observed no obvious differences in the expression of
BZLF1, BALF2, BMRF1, BGLF4, or gB proteins among the wild-type,
frameshift mutant (dBGLF3.5-Frame), and stop codon mutant
(dBGLF3.5-Stop) viruses (Fig. 5A).
We then examined the levels of viral DNA genome (Fig. 5B)
and production of infectious progeny viruses (Fig. 5C) by the
point mutant virus. The extent of lytic viral DNA ampliﬁcation
in the frameshift and stop codon mutant viruses was equiva-
lent to that in the wild-type virus (Fig. 5B). In addition, the
levels of progeny virus production were almost comparable
between the clones. Taken together, these results indicate that
BGLF3.5 knockout had no inﬂuence on EBV lytic replication in
HEK293 cells.
Production of BGLF3.5 protein in the context of virus infection
In the previous part of the manuscript, we have demon-
strated that the BGLF3.5 gene is not required for lytic replica-
tion of EBV at least in HEK293 cells. However, because we did
not detect BGLF3.5 protein expressed in virus-infected cells, we
could not dismiss the possibility that BGLF3.5 protein might
not be produced at all. In fact, we prepared antibody against
BGLF3.5 protein but it could not detect the protein in lytically
induced cells whereas it clearly could detect exogenously
overexpressed BGLF3.5 protein (not shown). In order to some-
how prove the existence of the protein in infected cells, we
added HA epitope in the ORF of BGLF3.5 gene, assuming that
BGLF3.5 protein level was very low in the context of virus
infection (Fig. 6A). The epitope sequence was inserted in the
middle of BGLF3.5 ORF (between E20 and K21) because we
knew that BGLF3.5 is not required for the virus replication and
also because N-terminus and C-terminus of this gene product
overlap with BGLF3 and BGLF4, respectively. Similar strategy
was actually employed in recent reports on KSHV for detection
of ORF35 protein (homolog of BGLF3.5) (Kronstad et al., 2013,
2014). After conﬁrmation of integrity of the recombinant EBV-
BAC genome (Fig. 6B), we analyzed if HA-tagged BGLF3.5 could
be visible in the course of lytic infection. As expected, we
successfully could detect HA-tagged BGLF3.5 protein by immu-
noblotting in the two representative samples (Fig. 6C). The HA-
tagged BGLF3.5 protein was detected at the size of 18 kDa
(Fig. 6D). Interestingly, protein of the downstream gene, BGLF4,
was decreased in both samples of BGLF3.5iHA mutants when
compared to wild-type cases (Fig. 6C). It is speculated that
insertion of even a very short sequence like HA epitope
inﬂuenced protein synthesis of BGLF4 protein. Either way,
BGLF3.5 protein was surely present in lytic cells, albeit faintly.
Effect of uORFs on protein synthesis rate of BGLF3.5 and BGLF4
It was recently reported that short uORFs near the AUG
codon of ORF35 upregulate ORF36 re-initiation in KSHV, but at
the same time, they clearly downregulate the ORF35 transla-
tion rate (Kronstad et al., 2013, 2014). In order to test whether
the short uORFs conserved near the initiation codon of EBV
BGLF3.5 might act in the similar manner, we point-mutated
initiation codons of the two uORFs in the context of virus
genome (Fig. 7A and B). Unexpectedly, however, BGLF4 protein
levels were not decreased, if any, by disruption of the two
uORFs (Fig. 7C), although we introduced same mutations in
EBV genome as previous KSHV reports (Kronstad et al., 2013,
2014). Therefore, there might be a slight difference between
EBV and KSHV in terms of translational control.
Discussion
In this study, we explored the physiological signiﬁcance of
the BGLF3.5 gene in EBV lytic replication. EBV BGLF3.5 has not
been studied previously. Furthermore, a misunderstanding in
the literature identiﬁes BGLF3, not BGLF3.5, as the homolog of
HSV UL14, despite the sequence similarity among BGLF3.5 and
UL14 (Mills et al., 2003). Interestingly, while HSV UL14 is not
essential for virus propagation, ORF35 was reportedly essential
for MHV-68 lytic replication (Song et al., 2005). However, using
recombinant EBVs devoid of BGLF3.5 by marker cassette inser-
tion or point mutations, we demonstrate that BGLF3.5 is not
required EBV replication in HEK293 cells. The BGLF3.5 knock-
out EBV may not be able to replicate efﬁciently in B lympho-
cytes, similar to UL14 knockout HSV (Yamauchi et al., 2008).
However, there is no appropriate B cell system in which
recombinant B95-8 EBV can efﬁciently execute the lytic repli-
cation cycle: thus, we cannot test this possibility. In either case,
we suggest that the data that MHV-68 is essential for lytic
Fig. 3. Trans complementation of the decreased yield of BGLF3.5 insertion virus. (A) HEK293 cells carrying the wild-type or dBGLF3.5-Ins EBV genomes were transfected with
the BZLF1 expression vector, together with the BGLF3.5 expression vector (Zþ3.5, gray bars), Flag-tagged BGLF4 PK expression vector (Zþ4, black bars), or its empty vector
(Zþpc, white bars). Three days after transfection, samples were harvested and Akata(-) cells were infected with these samples, followed by FACS analysis. Independent three
biological replicates were assayed and Student's t test was carried out. ** indicates po0.005 and # indicates p40.05. (B) Expression levels of BZLF1, BALF2, BMRF1, BGLF4, gB,
and tubulin proteins in (A) were measured by IB.
T. Watanabe et al. / Virology 483 (2015) 44–53 47
replication (Song et al., 2005) should be re-examined. Recently,
Glaunsinger's group clearly demonstrated that KSHV ORF35-36
(homolog of BGLF3.5-BGLF4) genes are transcribed as a bicis-
tronic (or even polycistronic) mRNA, and short uORFs near the
AUG codon of ORF35 regulate ORF36 re-initiation (Kronstad et
al., 2013, 2014). Because it is quite likely that this mechanism of
ORF36 (BGLF4) translation is conserved in EBV and MHV-68,
too, the insertion of a signature-tagged transposon into ORF35
of MHV-68 (Song et al., 2005) might have caused unexpected
loss in ORF36 translation, leading to overestimation of the
function of ORF35. In fact, MHV-68 growth is signiﬁcantly
restricted by an ORF35 nonsense mutation, but the gene was
not essential for infectious progeny production (Ohno et al.,
personal communication).
As to EBV PK, many researchers have demonstrated that the PK
is needed for efﬁcient production of progeny virus. Some groups
also have shown that BGLF4 PK plays an important role in optimal
production of a subset of viral genes (i.e., L genes) (El-Guindy et al.,
2014; Feederle et al., 2009; Gershburg et al., 2007; Whitehurst et
al., 2013). In Figs. 2 and 3B, protein levels of gB were slightly weak
in dBGLF3.5-Ins, in which BGLF4 expression was blocked. Ectopic
supply of Flag-tagged BGLF4 could even restore the decreased gB
production (Fig. 3B). Therefore, our data may serve to strengthen
those previous reports.
In Fig. 6C, insertion of HA epitope sequence in the middle of
BGLF3.5 ORF caused slight loss in amount of BGLF4 protein. This
phenomenon may also be accounted by the termination/re-initia-
tion mechanism. Because the HA epitope sequence unexpectedly
contains ATG, (which is not in frame, though) the ribosomes might
stop scanning and start re-initiation here, instead of the AUG
codon of BGLF4. This hypothesis has already been tested in KSHV,
where introduction of artiﬁcial start codon in the middle of ORF35
Fig. 4. Construction of point mutants of EBV BGLF3.5. (A) Schematic depiction of recombination of the EBV genome using the selection marker cassette. Tandemly arranged
neomycin-resistance and streptomycin-sensitivity genes were inserted between nts 60 and 61 of the BGLF3.5 gene to generate dBGLF3.5. The Neo/St cassette was then
replaced with a BGLF3.5 sequence with a stop codon or frameshift mutation to construct dBGLF3.5-Stop or dBGLF3.5-Frame. (B) Electrophoresis of the recombinant viruses.
EBV-BAC DNAs were digested with BamHI or EcoRI, and separated by agarose gel electrophoresis.
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Fig. 5. Viral protein expression (A), DNA synthesis (B), and progeny production (C) in the wild-type, BGLF3.5 point mutant with a stop codon, and the mutant with
frameshift. (A) HEK293 cells, latently infected with the indicated EBV genomes, were transfected with the BZLF1 expression vector, and harvested on day 2. IB was carried
out with anti-BZLF1, -BALF2, -BMRF1, -BGLF4, -gB, and -tubulin antibodies. (B) HEK293 cells with the indicated EBV genomes were transfected with the BZLF1 expression
vector, and harvested on day 2. Levels of viral DNAwere determined by qRT-PCR as described in the Materials and Methods. Three independent transfections were carried
out for measurement of EBV genome and control DNAs. (C) HEK293 cells carrying the indicated EBV genomes were transfected with the BZLF1 expression vector, and
harvested on day 3. After freezing/thawing, the supernatants were co-cultured with Akata(-) cells. GFP-positive cells were counted by FACS. Independent three biological
replicates were assayed and Student's t test was carried out. # indicates p40.05.
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ORF caused loss in ORF36 translation without affecting ORF35
protein levels (Kronstad et al., 2013, 2014).
The data in Fig. 7 that point mutation of the two uORFs did not
inhibit BGLF4 protein expression was unexpectable. Because termina-
tion/re-initiation is a complicated system that depends not only on the
nucleotide sequence but also on higher-order structure of mRNA,
introduction of mutations in the uORFs might simultaneously alter the
conformation of BGLF3.5/BGLF4 di-cistronic mRNA.We have onemore
example that translation of EBV BGL;F3.5/BGLF4 is very delicate and
difﬁcult to deal with; in order to analyze the physiological role of
kinase activity of BGLF4, we previously made kinase-dead EBV-BAC by
introducing K102I one point mutation in the BGLF4 protein. Although
the sequence was completely correct, this BGLF4 K102I mutant virus
unexpectedly failed to produce BGLF4 protein at all. Therefore, the
K102I mutation might also affect the higher-order conformation of the
dicistronic mRNA (not shown).
One might argue that BGLF3.5 must not be entirely non-
essential according to the data from HSV and MHV-68, but the
observation that BGLF3.5 is not required for lytic replication in
HEK293 was not surprising. To our knowledge, three groups
have reported on BGLF4 knockout viruses: two of the groups
have disabled BGLF3.5 or introduced unintended point muta-
tion into the BGLF3.5 gene. We ﬁrst reported in 2009 on an
insertion mutant, revertant, and the mutant with ﬂippase (FLP)
recognition target (FRT) sequence, in which the marker cas-
sette was removed and only the FRT sequence was left
(thereby, in-frame BGLF4 PK expression is prevented by the
34-bp FRT sequence) (Murata et al., 2009a). In 2009, a group in
Germany constructed a BGLF4 mutant that lacked most of the
BGLF4 ORF, but the deletion led to an unintended loss of BG-
LF5 expression (Feederle et al., 2009). The mutant actually
lacked a signiﬁcant portion of the BGLF3.5 gene, as well,
because BGLF3.5 and BGLF4 ORFs overlap. Another constructed
mutant in the paper lacked both BGLF4 and BGLF5, and was
again devoid of a signiﬁcant part of BGLF3.5. The authors
recognized that BGLF3.5 might be missing, but reported that
an exogenous supply of BGLF4 and BGLF5 to the mutant viruses
could markedly restore the progeny titer, and further addition
of BGLF3.5 did not increase the progeny levels (Feederle et al.,
2009), suggesting that BGLF3.5 may not be needed for lytic
replication. In 2010, a US group reported on a BGLF4 knockout
mutant that contains two stop codons at residues 1 and 5 of the
PK gene (Meng et al., 2010). However, this mutation also
caused unintended alteration of amino acid residues in the C-
terminus of BGLF3.5. This mutant virus was impaired in its
release of infectious virus particles, and this impairment could
be fully rescued by exogenous BGLF4 expression (Meng et al.,
2010). These results support our data indicating that BGLF3.5 is
not required for the execution of the lytic cycle program at
least in HEK293 cells.
We report that the BGLF3.5 gene is not required for the EBV lytic
cycle, and that uORFs of BGLF3.5 may play a role in translation of
BGLF3.5 and BGLF4. Further studies are required to clarify the sign-
iﬁcance of BGLF3.5 and the uORFs.
Materials and methods
Cell culture and reagents
HEK293 cells or their derivatives were maintained in Dulbec-
co's modiﬁed Eagle's medium (Gibco BRL) supplemented with 10%
Fig. 6. Identiﬁcation of HA-tagged BGLF3.5 protein. (A) Schematic depiction of recombination of the EBV genome using the selection marker cassette. Tandemly arranged
neomycin-resistance and streptomycin-sensitivity genes were inserted between nts 60 and 61 of the BGLF3.5 gene to generate dBGLF3.5-Ins (see Fig. 1). The Neo/St cassette
was then replaced with a BGLF3.5 sequence with HA epitope inserted in frame to construct BGLF3.5iHA. (B) Electrophoresis of the recombinant viruses. EBV-BAC DNAs were
digested with BamHI or EcoRI, and separated by agarose gel electrophoresis. (C) HEK293 cells, latently infected with the wild-type EBV or BGLF3.5iHA genome, were
transfected with the BZLF1 expression vector, and harvested on day 3. IB was carried out with anti-HA, -BGLF4, -BALF2, and -tubulin antibodies. (D) The samples of
BGLF3.5iHA in (C) were subjected to IB with anti-HA antibody. Size markers are also shown. * indicates cross-reaction with a host protein.
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fetal bovine serum. Akata(-) cells were cultured in RPMI1640
medium containing 10% fetal bovine serum. Antibodies against
BZLF1, BGLF4, BMRF1, BALF2, BALF5, and BALF4 were as repo-
rted earlier (Asai et al., 2006; Murata et al., 2009a). Anti-tubulin
antibody was purchased from Cell Signaling. Horseradish pero-
xidase-linked goat antibodies to mouse or rabbit IgG were from
Amersham Biosciences.
Plasmid construction
Two expression vectors, pcDNABZLF1 and pcDNAFlagBGLF4
have been reported previously (Murata et al., 2009a, 2009b).
The expression vector for BGLF3.5 (pcDNABGLF3.5) was gener-
ated by cloning the BGLF3.5 gene into pcDNA3. Primers used for
BGLF3.5 ampliﬁcation were as follows: 50-TCTGAATTCATGAA-
GATGAGTAGTTCTAAG-30 (forward), and 50-AGCGGCCGCTCAAT-
GACAGTCACCTTCCCC-30 (reverse), where underlined sequences
denote EcoRI and NotI recognition motifs, respectively.
Genetic manipulation of EBV-BAC DNA
EBV-BAC DNA was provided by W. Hammerschmidt (Delecluse
et al., 1998). Homologous recombination was carried out in
Escherichia coli as described previously (Isomura et al., 2008,
2004; Murata et al., 2009a, 2013).
To obtain recombinant viruses, the kanamycin resistance
gene and the streptomycin sensitivity gene in the rpsL-neo
(Gene Bridges, Germany) were employed. DNA fragments for
recombination were generated by PCR, using the rpsL-neo
vector as a template, with the following primers; 50-ATGAA-
GATGAGTAGTTCTAAGCGAGATCTGGTGGCCCAGCAACTAAGAGC-
CTCGGTAGAAGGCCTGGTGATGATGGCGGGATC-30#(forward)#
and 50-TGTTTCAAACAGAGCGTGGTCCCTCCCAAATCTGTCACGTG
CGCTCACAGCCGCTCTCTTTCAGAAGAACTCGTCAAGAAGG#-30#
(reverse), where underlined nucleotides denote sequences
identical to EBV BGLF3.5 gene. Recombination was checked
using the following primers; 50-TGATCTGGGCTCCATAGTTG-30
(forward) and 50-GCTGTTTGGACTCAAACGTC-30 (reverse).
Revertant viruses were generated using the PCR fragment
ampliﬁed by the above check primers. To produce frameshift
mutant and stop codon mutant, DNA fragment of the follow-
ing DNA sequences were used; 50-ATGGTGACTTATGAAGAT-
GAGTAGTTCTAAGCGAGATCTGGTGGCCCAGCAACTAAGAGCCTC
GGTAGAAA-GAGAGCGGCTGTGAGCGCACGTGACAGATTTGGGAG
GGACCACGCTCTGTTTGAAACACAGTTTACAT-30 (frameshift, where
the hyphen indicates an omitted nucleotide) and 50-ATGGTGACT-
TATGAAGATGAGTAGTTCTAAGCGAGATCTGGTGGCCCAGCAACTAAGA
GCCTCGGTATAATAGAGAGCGGCTGTGAGCGCACGTGACAGATTTGGGA
GGGACCACGCTCTGTTTGAAACACAGTTTACAT-30 (stop codon, where
underlined nucleotides are placed to generate two tandem stop
codons shown in italic). In order to construct EBV-BAC with BGLF3.5
labeled with HA epitope, HA sequence was inserted in frame
between E20 (GAA) and K21 (AAG) of BGLF3.5. The following DNA
sequence was used for recombination; 50-ATGGTGACTTATGAAGAT-
GAGTAGTTCTAAGCGAGATCTGGTGGCCCAGCAACTAAGAGCCTCGGTA
GAAGCTTACCCATACGATGTTCCAGATTACGCTAAGAGAGCGGCTGTGA-
GCGCACGTGACAGATTTGGGAGGGACCACGCTCTGTTTGAAACACAGTT
TACAT-30 (underlined nucleotides encode HA epitope).
For site-directed mutagenesis of uORFs, Neo/st cassette was newly
designated to target N-terminus of BGLF3.5 gene. DNA fragments for
recombination were generated by PCR, using the rpsL-neo vector as a
template, with the following primers; 50- GTGGACGCTGTGGGAAAT-
TACCGGGAAGCCTCCACTGGAACTACCGTACTCTACCCCACGTGGCCTGGT-
GATGATGGCGGGATC-30#(forward)#and#50-CGAGGCTCTTAGTTGCTG-
GGCCACCAGATCTCGCTTAGAACTACTCATCTTCATAAGTCACTCAGAAGA
ACTCGTCAAGAAGG-30 (reverse), where underlined nucleotides denote
sequences identical to N-terminus of BGLF3.5 gene. Then the following
DNA sequence was used for recombination; 50-GAGAGGCAGAAAGA-
TATATGGTGGACGCTGTGGGAAATTACCGGGAAGCCTCCACTGGAACTAC-
CGTACTCTACCCCACGTAGAATCTGGGCTCCATAGTTGCGGATTTGGTGAC-
TTATGAAGATGAGTAGTTCTAAGCGAGATCTGGTGGCCCAGCAACTAAG
AGCCTCGGTAGAAAAGAGAGCGGCTGTGAGCGCACGTGACAGATT-30
(underlined nucleotides indicate mutated sequence).
Fig. 7. Disruption of uORFs in the 50UTR of BGLF3.5. (A) Schematic depiction of
recombination of the EBV genome using the selection marker cassette. Tandemly
arranged neomycin-resistance and streptomycin-sensitivity genes were inserted
around the uORFs to generate intermediate. The Neo/St cassette was then replaced
with a sequence with mutations at the initiation codons of two uORFs.
(B) Electrophoresis of the recombinant viruses. EBV-BAC DNAs were digested with
BamHI or EcoRI, and separated by agarose gel electrophoresis. (C) HEK293 cells,
latently infected with the wild-type or duORFs EBV genome, were transfected with
the BZLF1 expression vector, and harvested on day 2. IB was carried out with anti-
BZLF1, -BGLF4, -BALF2, and -tubulin antibodies.
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Electroporation was performed using Gene Pulser III (Bio-Ran)
and puriﬁcation of EBV-BAC DNA was achieved with NucleoBond
Bac100 (Macherey-Nagel, Germany).
Transfection, cell cloning and IB
EBV-BAC DNA was transfected into HEK293 cells using the
Lipofectamine 2000 reagent (Invitrogen). After transfection of BAC
DNA, the cells were cultured on 10-cm dishes with 150 μg/ml of
hygromycin B for 10–15 days and GFP-positive cell colonies were
cloned as described previously (Murata et al., 2009a). Shortly, for
each recombinant virus, we picked up more than 10 hygromycin-
resistant, GFP-positive cell colonies and examined if the cells exhib-
ited minimal spontaneous expression of viral lytic proteins, and
signiﬁcant induction of them upon BZLF1 transfection.
To induce lytic replication, HEK293 cells were transfected with
pcDNABZLF1 using the Neon system (Invitrogen). Forty-eight
hours after transfection, the cells were washed with PBS and
harvested for IB as described previously (Murata et al., 2009a).
Quantiﬁcation of viral DNA synthesis during lytic replication
Levels of viral DNA were determined by quantitative real-time
PCR (qRT-PCR) as described previously (Narita et al., 2013). Brieﬂy,
cells in lysis buffer were sonicated, and treated with proteinase K.
After inactivation of the proteinase, qRT-PCR was performed in
10 μl of solution containing 1 μM of each forward and reverse
primer, 5 μl of FastStart Universal Probe Master (Rox) (Roche
Applied Science), eukaryotic 18 S rRNA endogenous control
(Applied Biosystems), and 1 μl of prepared sample DNA in PCR
lysis buffer. The intensity of the Rox dye was used to compensate
for volume ﬂuctuations among the tubes. A standard curve was
constructed using serial dilutions of DNA and was used to quantify
the amount of DNA. Primers and a probe for the detection of the
viral genome were designed within the BALF2-coding region. The
sequences were as follows: 50-GCCCGTCCGGTTGTCA-30 (forward
primer), 50-AATATCTGGTTGTTGCCGTTGA-30 (reverse primer), and
50-FAM-CTGCCAGTGACCATCAACAAGTACACGG-TAMRA-30 (probe;
where FAM is 6-carboxyﬂuorescein and TAMRA is tetramethyl
rhodamine).
FACS analysis
Akata(-) cells were infected with HEK293 culture supernatant.
After 48 h, Akata(-) cells were ﬁxed with 1% formaldehyde, washed
with PBS and suspended in PBS. GFP-positive cells were counted
using the FACS Calibur G5 system (Becton-Dickinson), according to
the manufacturer's instructions. Contamination of producer cells
(HEK293 EBV-BAC) or the cell debris was excluded by gating on
the FSC/SSC dot plot.
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